Research ArticleExperimental Studies

TBX15 rs98422, DNM3 rs1011731, RAD51B rs8017304, and rs2588809 Gene Polymorphisms and Associations With Pituitary Adenoma

GABIJA JUKNYTĖ, INGA LAURINAITYTĖ, ALVITA VILKEVIČIŪTĖ, GRETA GEDVILAITĖ, BRIGITA GLEBAUSKIENĖ, LORESA KRIAUČIŪNIENĖ and RASA LIUTKEVIČIENĖ
In Vivo March 2021, 35 (2) 815-826; DOI: https://doi.org/10.21873/invivo.12322

Abstract

Background: Pituitary adenoma (PA) is a benign tumor of parenchymal cells in the adenohypophysis, and it’s development is strongly associated with genetic factors.This study aim was to find whether TBX15 rs98422, DNM3 rs1011731, RAD51B rs8017304, and rs2588809 single nucleotide polymorphisms can be associated with pituitary adenoma. While the TBX15 gene belongs to the T-box family of genes and is a transcription factor involved in many developmental processes, the DNM3 encodes a protein that is a member of the dynamin family with mechanochemical properties involved in actin-membrane processes, predominantly in membrane budding, and the RAD51B gene plays a significant role in homologous recombination in DNA repair for genome stability. Materials and Methods: The study enrolled 113 patients with pituitary adenoma and 283 healthy control subjects. DNA samples were extracted and purified from peripheral blood leukocytes. Genotyping was carried out using real-time polymerase chain reaction. The results were assessed using binomial logistic regression. Results: Our study revealed that RAD51B rs2588809 TT genotype could be associated with PA development in the co-dominant (OR=6.833; 95% CI=2.557-18.262; p<0.001) and recessive (OR=7.066; 95% CI=2.667-18.722; p<0.001) models. The same results were observed in females but not in males and PA without recurrence, while in PA with recurrence, no statistically significant results were obtained. Conclusion: RAD51B rs2588809 TT genotype may increase the odds of PA development in women; it may also be associated with non-recurrent PA development.

Pituitary adenoma (PA) is an intracranial tumor localized in the bone cavity (sella turcica) surrounded by multiple neural, vascular, endocrine, and bone structures, which further may contribute to an assortment of tumor types (1-7). PA accounts for approximately 15 to 20 percent of primary brain tumors with a prevalence of 77.6-97.6 PA cases per 100,000 individuals. Clinically significant PAs occur in one out of 1064 individuals (5-11). PA can occur insidiously – most patients do not realize they have it until specifically investigated. This tumor can manifest in two ways: an endocrine imbalance or pressure on the surrounding structures. The latter is the most common form of macroadenoma manifestation (12). Six to ten percent of all PAs expand into the cavernous sinus (13, 14). The optic chiasm is directly above the pituitary gland, so a prolonged compression of the chiasm can cause primary optic nerve atrophy and result in visual function defects, such as decreased visual acuity and visual field defects or impaired color vision (15). The earlier the tumor is diagnosed, the more likely it is to be removed and the visual function to be preserved. Endocrine changes may be due to the overexpression of tumor hormones or hypoexpression, when the tumor compresses the pituitary gland (16).

The etiology and pathogenesis of PA are complex and still poorly understood. PA represents a heterogeneous disease whose pathogenesis is a multifactorial process that involves both environmental and genetic factors. Therefore, a better understanding of the PA pathogenesis requires a comprehensive research of this disease’s biological and genetic markers. Plenty of possible molecular markers, as well as intelrleukin 9 variant rs1859430, which might be incorporated in the tumorogenesis of PAs, are currently under investigation (17). Recent studies focus on genetic markers for cancer development, so we aimed to elucidate the role of four TXB15, DNM3 and RAD51B single nucleotide variants in PA development. The elevated genes has been reported in a variety of cancers, including prostate, ovarian cancers. However, the data regarding TBX15, DNM3 and RAD51B genes and PA is still lacking (18-20).

TBX15, a T-box family member, is possibly involved in cancer cell transformation because of its antiapoptotic function (18). It also is known that T-box genes are involved in in carcinogenesis (21-23). TBX15 is associated with prostate (24), thyroid cancer (19, 25, 26), ovarian carcinoma (20).

The other marker dynamin 3 (DNM3) is a candidate tumor suppressor gene. This gene encodes a member of the dynamin family, which possesses mechanochemical properties to tabulate and sever membranes (27). However, few reports describe the relationship between DNM3 and malignant diseases (28, 29). DNM3 has been found mainly in the brain (at a lower level than DNM1) and testicles, and less frequently in the lungs and heart (30). The importance of the DNM3 gene has been investigated in gliomas (31, 32), hepatocellular carcinoma (33-35), colon cancer (36), and papillary thyroid carcinoma (37). Few studies have investigated the association between DNM3 and hepatocellular carcinoma, breast cancer, T-cell lymphoma, colon cancer (28-30, 33-34, 38, 39). Additionally, the importance of DNM3 was investigated in brain tumors glioblastomas (31-32).

RAD51B plays a role in homologous DNA pairing and strand exchange in DNA double-strand break repair (38, 40). The importance of RAD51B has previously been investigated in the breast, ovarian, lung cancer and uterine leiomyomas (31, 41-43). Also, some studies have been carried out to look for the possible association between the RAD51 gene variants and pancreatic (44-47), prostate cancer (48, 49), malignant melanoma (50), colorectal adenocarcinoma (51), endometrial cancer (52), soft tissue sarcoma (53) and glioblastoma (54).

Our study aimed to determine associations between TBX15 rs98422, DNM3 rs1011731, RAD51B rs8017304, rs2588809 single nucleotide polymorphisms and pituitary adenoma invasiveness, development, and recurrence.

These findings support the hypothesised role of TBX15, DNM3 and RAD 51 as tumour promoters. Based on the TBX15, DNM3 and RAD51B associations with cancerous processes we selected four widely described SNPs located in these genes. According to the dbSNP database (https://www.ncbi.nlm.nih.gov/snp/) the minor allele frequencies of these intronic variants (TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304, rs2588809) are more than 0.1 in the Europe population, and none of these variants have been studied with PA development, invasiveness, PA activity and recurrence. The aim of the present study was to determine these associations.

Materials and Methods

Patients and selection. This study was carried out at the Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences and Laboratory of Ophthalmology, Neuroscience Institute, Lithuanian University of Health Sciences. The Ethics Committee for Biomedical Research at Lithuanian University of Health Sciences (LUHS) approved the study (number BE-2-47). All subjects provided written informed consent under the Declaration of Helsinki. Based on our inclusion and exclusion criteria (55), two groups were formed in the study: the PA group (n=113) and the control group (n=283).

Evaluation of PA hormonal activity, invasiveness, recurrence and DNA extraction and genotyping. The analysis of all pituitary adenomas was based on histopathological findings of PA and hormone levels in the blood serum before surgery. All PA subjects were categorized into two groups – active and inactive PA (56).

Since some of the subjects had already had surgery in recent years, we categorized them by recurrence of pituitary adenoma into two groups – PA with and without recurrence.

Pituitary adenoma recurrence was diagnosed when enlargement of a residual tumor or a new growth was documented on follow-up magnetic resonance imaging (MRI) after surgical resection during the period of this study. The residual tumor was considered stable if there no signs of tumor progression on follow-up MRI. Most prolactinomas were surgically treated because of the remaining pressure effects of surrounding structures or ineffective medical treatment.

PA invasiveness has been described previously (55). The suprasellar extension and sphenoid sinus invasion by PA were classified according to the Hardy classification modified by Wilson, and the degree of suprasellar and parasellar extensions was graded as stages A–E. The degree of sellar floor erosion was graded as grades I-IV. Grade III shows localized sellar perforation, and grade IV shows diffuse destruction of sellar floor, which are the signs of invasive PA. The Knosp classification system was used to quantify the invasion of the cavernous sinus. Grade 3 and 4 pituitary tumors were considered to be invasive.

DNA was extracted from 200 μL venous blood (white blood cells) using the silica-based membrane technology utilizing a genomic DNA extraction kit (GeneJET Genomic DNA Purification Kit, Thermo Scientific, MA, USA), according to the manufacturer’s recommendations. The genotyping of TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304 and rs2588809 was carried out using the real-time PCR. SNPs were genotyped on the Step One Plus real-time PCR system (Applied Biosystems, Foster City, CA, USA). The TaqMan® SNP genotyping assays (Thermo Scientific) for all SNPs were performed according to the manufacturer’s protocol. The Allelic Discrimination program was used during the real-time PCR. The program determined individual genotypes according to the fluorescence intensity rate of different detectors (VIC and FAM).

Statistical analysis. The age of study participants was presented as the median and interquartile range (IQR). It was compared between both study groups using the nonparametric Mann-Whitney U-test. All categorical variables of TBX15 rs98422, DNM3 rs1011731, RAD51B rs8017304 and rs2588809 genotypes and alleles were expressed as absolute numbers with percentages in brackets and compared using the Pearson’s χ2 and Fisher’s exact test (when n<50) in both groups. Binomial logistic regression analysis was performed to evaluate the genotype and allele impact on PA development and reported as odds ratios (ORs) with 95% confidence intervals (CIs). The lowest values of the Akaike information criterion (AIC) showed the best genetic models. Statistically significant differences were reported when p<0.05, but for multiple comparisons, the Bonferroni correction was applied with the p<0.05/4 (since we analyzed four different SNPs).

Results

A total of 396 individuals were included in the study. Two groups of subjects were formed during the study. The first one included patients with pituitary adenoma, the second included healthy subjects (control group). The characteristics of the subjects are presented in Table I. The first group consisted of 113 individuals, of whom 45 (39.8%) were men, and 68 (60.2%) were women. The median age of this group was 54 years. The control group consisted of 100 (35.3%) men and 183 (64.7%) women. In total, the control group consisted of 283 individuals with a median age of 55.5 years.

View this table:
Table I.

Characteristics of study subjects.

TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304, and RAD51B rs2588809 genotype frequencies in the pituitary adenoma and healthy population groups. Hardy Weinberg analysis was performed to compare the observed and expected frequencies of TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304, and RAD51B rs2588809 using the χ2 test in the control group. The genotype distribution of the polymorphisms matched the Hardy-Weinberg equilibrium. (p>0.001) (57). TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304, and RAD51B rs2588809 genotypes and allele frequencies did not significantly differ between the PA and control groups. The results are shownin Table II.

View this table:
Table II.

TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304 and RAD51B rs2588809 genotype and allele frequencies in the PA patient and control groups.

Binomial logistic regression analysis was performed to estimate the impact of genotypes and alleles on PA development. Binomial logistic regression analysis of RAD51 rs2588809 revealed that the TT genotype was associated with about 7-fold increased odds of PA development in the co-dominant (OR=6.833; 95% CI=2.557-18.262; p<0.001) and recessive (OR=7.066; 95% CI=2.667-18.722; p<0.001) models. Each copy of the T allele was associated with increased odds of PA development (OR=1.627; 95% CI=1.135-2.334; p=0.008) (Table III). Analysis of TBX15 rs984222, DNM3 rs1011731, and RAD51B rs8017304 did not show any statistically significant results (Supplementary material).

View this table:
Table III.

Binary logistic regression analysis of RAD51B rs2588809.

Comparison of TBX15 rs984222, DNM3 rs101173, RAD51B rs8017304, and rs2588809 polymorphisms in pituitary adenoma patients by gender. Statistical analysis was also performed to compare the TBX15 rs984222, DNM3 rs101731, and RAD51 rs8017304 genotype and allele frequencies between the patients with PA and control group subjects by their gender (Table IV). The analysis of RAD51B rs2588809 showed a statistically significant difference in the CC, CT, and TT genotype distributions between females with PA and control females (69.12%, 16.18%, and 14.7% vs. 67.21%, 27.87%, and 4.92%, respectively, p=0.011). The results are presented in Table IV.

View this table:
Table IV.

TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304 and RAD51B rs2588809 genotype and allele frequencies in PA patients and controls by gender.

Binominal logistic regression was performed to evaluate these polymorphisms’ impact on the PA development in men and women, separately. Binominal logistic regression analysis in the women’s group showed that the TT genotype was associated with 6.7-fold higher odds of PA development in the co-dominant model (OR=6.744; 95% CI=2.021-22.583; p=0.002) and with 7.7-fold increased odds of PA development in the recessive model (OR=7.716; 95% CI=2.332-25.533; p=0.001). The results are shown in Table V. The TBX15 rs984222, DNM3 rs1011731, and RAD51B rs8017304 were not associated with female PA development (Supplementary material). Also, no statistically significant variables were found in the men’s group (Supplementary material).

View this table:
Table V.

Binary logistic regression analysis of RAD51B rs2588809 in females.

Association of TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304, and RAD51B rs2588809 polymorphisms with clinical and morphological features of PA. One of our study’s objectives was to determine if there is a relationship between TBX15, DNM3, and RAD51B gene polymorphisms with PA’s clinical and morphological features. Comparing the distribution of genotypes and alleles of TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304, and RAD51B rs2588809 between the PA groups by recurrence and the control group, we obtained statistically significant differences in the rs2588809 CC, CT, and TT genotype distributions between PA without-recurrence patients and healthy controls (67.03%, 17.58% and 15.39% vs. 69.96%, 24.73%, and 5.31%, respectively; p=0.005). The results are shown in Table VI. Regarding PA recurrence, we performed binominal logistic regression to evaluate the impact of TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304, and RAD51B rs2588809 polymorphisms on the development of PAs with and without recurrence. We found that the RAD15B rs2588809 TT genotype was associated with approximately 8-fold increased odds of development of PA without recurrence in the co-dominant (OR=7.842; 95% CI=2.890-21.277; p<0.001) and recessive model (OR=8.394; 95% CI=3.122-22.571; p<0.001). Also, each T allele was associated with 1.7-fold increased odds of development of PA without recurrence in the additive model (OR=1.676; 95% CI=0.114-2.457; p=0.008). The data are presented in Table VII. No associations were found in the recurrent PA group (Supplementary material). The TBX15 rs984222, DNM3 rs1011731, and RAD51B rs8017304 were not associated with PA recurrence (Supplementary material).

View this table:
Table VI.

TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304 and RAD51B rs2588809 genotype and allele frequencies in patients grouped by PA recurrence and healthy subjects.

View this table:
Table VII.

RAD51B rs2588809 association with PA without recurrence.

TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304, and RAD51B rs2588809 genotypes and allele frequencies were compared between the active and inactive PA and healthy control groups. We found that the RAD51B rs8017304 G allele was detected significantly more frequently in the inactive PA group vs. the control group (48.13% vs. 33.57%; p=0.004) (Table VIII).

View this table:
Table VIII.

TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304 and RAD51B rs2588809 genotype and allele frequencies in patients grouped by PA hormonal activity and healthy subjects.

Binominal logistic regression revealed that the RAD51B rs2588809 TT genotype was associated with increased odds of active PA development in the codominant (OR=6.058; 95% CI=2.146-19.734; p=0.001) and recessive (OR=7.103; 95% CI=2.366-21.320; p<0.001) models (Table IX). Also, the RAD51B rs2588809 TT genotype was associated with increased odds of inactive PA development in the codominant (OR=7.247; 95% CI=2.29-22.906; p=0.001) and recessive (OR=7.260; 95% CI=2.260-21.840; p=0.001) models. Each T allele at rs2588809 was associated with 1.9-fold increased odds of inactive PA development in the additive model (OR=1.865; 95% CI=1.154-3.014; p=0.011). These data are presented in Table IX. The TBX15 rs984222, DNM3 rs1011731 and RAD51 rs8017304 were not associated with PA hormonal activity (Supplementary material).

View this table:
Table IX.

RAD51B rs2588809 associations with PA hormonal activity.

We then compared the distribution of TBX15 rs984222, DNM3 rs1011731, RAD51 rs8017304, and rs2588809 genotypes and alleles in patients with invasive and non-invasive PAs vs. healthy controls. The RAD51B rs2588809 genotypes (CC, CT, and TT) were distributed significantly differently in patients with non-invasive PA and healthy subjects (59.09%, 22.72% and 18.19% vs. 69.96%, 24.73%, and 5.31%, respectively, p=0.008) (Table X). Also, the T allele occurred more frequently in patients with non-invasive PA than in control subjects (29.55% vs. 17.67%, p=0.008). The results are presented in Table X.

View this table:
Table X.

TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304 and RAD51B rs2588809 genotype and allele frequencies in patients grouped by PA invasiveness and healthy subjects.

Binominal logistic regression was performed in patients with PA by its invasiveness. It was revealed that the RAD51B rs2588809 TT genotype was associated with about 5-fold increased odds of invasive PA in the codominant (OR=4.881; 95% CI=1.570-15.172; p=0.006) and recessive (OR=5.212; 95% CI=1.693-16.050; p=0.004) models (Table XI). Also, the RAD51B rs2588809 TT genotype was associated with increased odds of non-invasive PA development in the codominant (OR=10.513; 95% CI=3.381-32.688; p<0.001) and recessive (OR=10.259; 95% CI=3.368-31.255; p<0.001) models. Each T allele was associated with 2.2-fold increased odds of non-invasive PA development in the additive model (OR=2.222; 95% CI=1.352-3.652; p=0.002). The results are shown in Table XI. The TBX15 rs984222, DNM3 rs1011731, and RAD51 rs8017304 were not associated with PA invasiveness (Supplementary material).

View this table:
Table XI.

RAD51B gene rs2588809 association with PA invasiveness.

Discussion

Our study analyzed the TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304 and RAD51B rs2588809 gene polymorphisms in PA patients (n=113) and healthy control subjects (n=283). The results were compared by gender, age, and the clinical course of the disease. Studies of these polymorphisms analyzing PA association with rs984222, rs1011731, rs8017304, and rs2588809 have not been performed yet, to the best of our knowledge.

The role of TBX family genes (TBX2 and TBX3) in oncogenic processes was associated with an increase of their expression level, as they have been found to be overexpressed in different types of cancer, including breast, cervical, ovarian, pancreatic, liver, and bladder cancer (58, 59). TBX15 hypermethylation has been evaluated in prostate and ovarian carcinomas (19, 20). No studies have been performed in association with any brain tumors, including PA. Our study was the first to find that the C allele of TBX15 rs984222 polymorphism reduced PA’s recurrence (p=0.037).

DNM3 has been shown to be involved in various malignancies (28-37). Marino et al. have reported DNM3 expression in the brain and testicles and less often in the lungs and heart (29). Inokawa et al. and Shen et al. have found that DNM3 is hypermethylated in hepatocellular cancer (HCC) (33-34). Zhang et al. have also studied the mechanism of DNM3 in HCC (60). Teicher et al. have reported liposarcoma 1q24.3 amplifications involving DNM3 (29) while low DNM2 expression has been associated with tumor invasion and metastasis in cervix carcinoma and up-regulation of matrix metalloproteinase 2 (MMP-2) expression (61). The DNM3 gene has also been investigated as a possible molecular marker for diagnosis and gene therapy of malignant diseases (38). Yang et al. have discussed the importance of the DNM3 gene in gliomas. As the DNM3 gene is the target of miR-221, the overexpression of DNM3 could reverse its tumor-promoting effect (31-32). Based on these findings, we sought to examine whether a polymorphism in the DNM3 promoter could impact PA development risk. Unfortunately, in our study, we did not find any statistically significant differences analyzing DNM3 rs1011731 gene polymorphism in relation to PA.

Concerning theother two gene polymorphisms, we found that the RAD51B rs2588809 CC genotype and the rs8017304 AG genotype might increase the probability of PA recurrence and invasiveness. Also, we proved that the RAD51B rs2588809 TT genotype might increase the odds of PA development in women and may be associated with PA development without recurrence. The RAD51B gene has previously been studied in other tumor types (breast, ovarian, and lung cancers (32, 41) but not in brain tumors, so we could not compare our results with the results of other authors.

RAD51B has been previously evaluated as a candidate gene for breast cancer predisposition, but no mutation was detected in a study of 188 multiple-case breast cancer families (62). Previous studies have identified chromosomal rearrangements disrupting RAD51B in benign tumors, particularly uterine leiomyomas (42, 43). In addition, the findings by Golmard and colleagues must be interpreted in the context of two genome-wide association studies (GWAS), which identified the minor allele of single nucleotide polymorphisms in RAD51B acting as a low-risk factor for breast cancer: the rs999737 (63) and rs1314913 (64), located in RAD51B introns 10 and 7, respectively. Results by Mengyin et al. also suggest that RAD51B could be a candidate prognostic factor for non-small cell lung cancer patients (41).

Overall, the present study of the TBX15 rs984222, DNM3 rs1011731, RAD51B rs8017304, and RAD51B rs2588809 gene polymorphisms requires future replication in studies with higher sample sizes to confirm the association of RAD51B rs2588809 with PA.

Conclusion

The RAD51B rs2588809 TT genotype was more common in women with PA than in healthy women, and the T allele was less frequent in men with PA than in healthy men. The RAD51B rs2588809 T allele increased the potential for PA invasiveness and PA activity. The likelihood of PA recurrence was reduced by the TT genotype and each T allele.

Footnotes

  • Authors’ Contributions

    Conceptualization, R.L., and B.G.; Data curation, A.V., G.G., and B.G.; Writing-Original draft preparation, I.L., G.J., and R.L; Methodology, A.V., G.G., B.G., L.K, and R.L.; Investigation, A.V., G.G., G.J., I.L., and L.K.; Validation, L.K., and R.L.; Supervision, R.L., and B.G.; Writing-Reviewing and Editing, R.L.

  • This article is freely accessible online.

  • Data Availability

    The genotyping data used to support the findings of this study is available from the corresponding author upon request.

  • Supplementary Material

    Available at: https://docs.google.com/document/d/1U5Za-8j3e9mbHEye0LJlEcwVPL1f7-uSt7HlwRpslqM/edit?usp=sharing.

  • Conflicts of Interest

    None of the Authors has any proprietary interests or conflicts of interest related to this submission.

  • Received November 5, 2020.
  • Revision received January 7, 2021.
  • Accepted January 11, 2021.

References

  1. ↵
    1. Mete O,
    2. Ezzat S and
    3. Asa SL
    : Biomarkers of aggressive pituitary adenomas. Mol Endocrinol 49(2): R69-78, 2012. PMID: 22822048. DOI: 10.1530/JME-12-0113
    OpenUrlCrossRef
    1. Feingold KR,
    2. Anawalt B,
    3. Boyce A,
    4. Chrousos G,
    5. de Herder WW,
    6. Dungan K,
    7. Grossman A,
    8. Hershman JM,
    9. Hofland J,
    10. Kaltsas G,
    11. Koch C,
    12. Kopp P,
    13. Korbonits M,
    14. McLachlan R,
    15. Morley JE,
    16. New M,
    17. Purnell J,
    18. Singer F,
    19. Stratakis CA,
    20. Trence DL,
    21. Wilson DP
    1. Drummond JB,
    2. Ribeiro-Oliveira A Jr. and
    3. Soares BS
    : Non-Functioning Pituitary Adenomas. 2018 Nov 28. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, Grossman A, Hershman JM, Hofland J, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Purnell J, Singer F, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 30521182.
    1. Raverot G,
    2. Jouanneau E and
    3. Trouillas J
    : Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol 170(4): R121-132, 2014. PMID: 24431196. DOI: 10.1530/EJE-13-1031
    OpenUrlAbstract/FREE Full Text
    1. Kovacs K,
    2. Horvath E and
    3. Vidal S
    : Classification of pituitary adenomas. J Neuro-Oncol 54(2): 121-127, 2001. PMID: 11761429. DOI: 10.1023/a:1012945129981
    OpenUrlCrossRefPubMed
  5. ↵
    1. Altay T,
    2. Krisht KM and
    3. Couldwell WT
    : Sellar and parasellar metastatic tumors. Int J Surg Oncol 2012: 647256, 2012. PMID: 22312541. DOI: 10.1155/2012/647256
    OpenUrlCrossRefPubMed
    1. Vandeva S,
    2. Jaffrain-Rea M,
    3. Daly AF,
    4. Tichomirowa M,
    5. Zacharieva S and
    6. Beckers A
    : The genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 24(3): 461-476, 2010. PMID: 20833337. DOI: 10.1016/j.beem.2010.03.001
    OpenUrlCrossRefPubMed
  7. ↵
    1. Dworakowska D and
    2. Grossman AB
    : The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23(5): 525-541, 2011. PMID: 19945021. DOI: 10.1016/j.beem.2009.05.004
    OpenUrlCrossRef
    1. Lake MG,
    2. Krook LS and
    3. Cruz SV
    : Pituitary adenomas: an overview. Am Fam Physician 88(5): 319-327, 2013. PMID: 24010395.
    OpenUrl
    1. Gruppetta M,
    2. Mercieca C and
    3. Vassallo J
    : Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16(4): 545-553, 2013. PMID: 23239049. DOI: 10.1007/s11102-012-0454-0.
    OpenUrlCrossRefPubMed
    1. Agustsson TT,
    2. Baldvinsdottir T,
    3. Jonasson JG,
    4. Olafsdottir E,
    5. Steinthorsdottir V,
    6. Sigurdsson G,
    7. Thorsson AV,
    8. Carroll PV,
    9. Korbonits M and
    10. Benediktsson R
    : The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur J Endocrinol 173(5): 655-664, 2015. PMID: 26423473. DOI: 10.1530/EJE-15-0189
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Day PF,
    2. Loto MG,
    3. Glerean M,
    4. Picasso MF,
    5. Lovazzano S and
    6. Giunta DH
    : Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina. Arch Endocrinol Metab 60(6): 554-561, 2016. PMID: 27982201. DOI: 10.1590/2359-3997000000195
    OpenUrlCrossRef
  12. ↵
    1. Bertolessi M,
    2. Linta L,
    3. Seufferlein T,
    4. Kleger A and
    5. Liebau S
    : A fresh look on T-Box factor action in early embryogenesis (T-Box factors in early development). Stem Cells Dev 24(16): 1833-1851, 2015. PMID: 25952667. DOI: 10.1089/scd.2015.0102
    OpenUrlCrossRef
  13. ↵
    1. Destrieux C,
    2. Kakou MK,
    3. Velut S,
    4. Lefrancq T and
    5. Jan M
    : Microanatomy of the hypophyseal fossa boundaries. J Neurosurg 88: 743-752, 1998. PMID: 9525722. DOI: 10.3171/jns.1998.88.4.0743
    OpenUrlCrossRefPubMed
  14. ↵
    1. Harris FS and
    2. Rhoton AL
    : Anatomy of the cavernous sinus: a microsurgical study. J Neurosurg 45: 169-180, 1976. PMID: 939976. DOI: 10.3171/jns.1976.45.2.0169.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Glebauskiene B,
    2. Liutkeviciene R,
    3. Zlatkute E,
    4. Kriauciuniene L and
    5. Zaliuniene D
    : Association of retinal nerve fibre layer thickness with quantitative magnetic resonance imaging data of the optic chiasm in pituitary adenoma patients. J Clin Neurosci 50: 1-6, 2018. PMID: 29398198. DOI: 10.1016/j.jocn.2018.01.005
    OpenUrlCrossRef
  16. ↵
    1. Ferrante E,
    2. Ferraroni M,
    3. Castrignanò T,
    4. Menicatti L,
    5. Anagni M,
    6. Reimondo G,
    7. Del Monte P,
    8. Bernasconi D,
    9. Loli P,
    10. Faustini-Fustini M,
    11. Borretta G,
    12. Terzolo M,
    13. Losa M,
    14. Morabito A,
    15. Spada A,
    16. Beck-Peccoz P and
    17. Lania AG
    : Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 155(6): 823-829, 2006. PMID: 17132751. DOI: 10.1530/eje.1.02298
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Mickevicius T,
    2. Vilkeviciute A,
    3. Glebauskiene B,
    4. Kriauciuniene L and
    5. Liutkeviciene R
    : Do TRIB1 and IL-9 gene polymorphisms impact the development and manifestation of pituitary adenoma? In Vivo 34(5): 2499-2505, 2020. PMID: 32871778. DOI: 10.21873/invivo.12066.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Arribas J,
    2. Giménez E,
    3. Marcos R and
    4. Velázquez A
    : Novel antiapoptotic effect of TBX15: overexpression of TBX15 reduces apoptosis in cancer cells. Apoptosis 20(10): 1338-1346, 2015. PMID: 26216026. DOI: 10.1007/s10495-015-1155-8
    OpenUrlCrossRef
  19. ↵
    1. Kron K,
    2. Pethe V,
    3. Briollais L,
    4. Sadikovic B,
    5. Ozcelik H,
    6. Sunderji A,
    7. Venkateswaran V,
    8. Pinthus J,
    9. Fleshner N,
    10. van der Kwast T and
    11. Bapat B
    : Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 4(3): e4830, 2009. PMID: 19283074. DOI: 10.1371/journal.pone.0004830
    OpenUrlCrossRefPubMed
  20. ↵
    1. Gozzi G,
    2. Chelbi ST,
    3. Manni P,
    4. Alberti L,
    5. Fonda S,
    6. Saponaro S,
    7. Fabbiani L,
    8. Rivasi F,
    9. Benhattar J and
    10. Losi L
    : Promoter methylation and downregulated expression of the TBX15 gene in ovarian carcinoma. Oncol Lett 12(4): 2811-2819, 2016. PMID: 27698863. DOI: 10.3892/ol.2016.5019
    OpenUrlCrossRef
  21. ↵
    1. Peres J,
    2. Davis E,
    3. Mowla S,
    4. Bennett DC,
    5. Li JA,
    6. Wansleben S and
    7. Prince S
    : The highly homologous T-box transcription factors, TBX2 and TBX3, have distinct roles in the oncogenic process. Genes Cancer 1(3): 272-282, 2010. PMID: 21779450. DOI: 10.1177/1947601910365160
    OpenUrlCrossRefPubMed
    1. Yu J,
    2. Ma X,
    3. Cheung KF,
    4. Li X,
    5. Tian L,
    6. Wang S,
    7. Wu CW,
    8. Wu WK,
    9. He M,
    10. Wang M,
    11. Ng SS and
    12. Sung JJ
    : Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer. Oncogene 29(49): 6464-74, 2010. PMID: 20802524. DOI: 10.1038/onc.2010.370
    OpenUrlCrossRefPubMed
  23. ↵
    1. Papaioannou VE
    : The T-box gene family: emerging roles in development, stem cells and cancer. Development 141(20): 3819-3833, 2014. PMID: 25294936. DOI: 10.1242/dev.104471
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Kron K,
    2. Liu L,
    3. Trudel D,
    4. Pethe V,
    5. Trachtenberg J,
    6. Fleshner N,
    7. Bapat B and
    8. van der Kwast T
    : Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res 18(10): 2896-2904, 2012. PMID: 22452941. DOI: 10.1158/1078-0432.CCR-11-2901
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Pacifico F and
    2. Leonardi A
    : Role of NF-kappaB in thyroid cancer. Mol Cell Endocrinol 321(1): 29-35, 2010. PMID: 19879919. DOI: 10.1016/j.mce.2009.10.010
    OpenUrlCrossRefPubMed
  26. ↵
    1. Xing M
    : Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13(3): 184-199, 2013. PMID: 23429735; PMCID: DOI: 10.1038/nrc3431
    OpenUrlCrossRefPubMed
  27. ↵
    1. Orth JD and
    2. McNiven MA
    : Dynamin at the actin-membrane interface. Curr Opin Cell Biol 15(1): 31-39, 2003. PMID: 12517701. DOI: 10.1016/s0955-0674(02)00010-8
    OpenUrlCrossRefPubMed
  28. ↵
    1. Booken N,
    2. Gratchev A,
    3. Utikal J,
    4. Weiss C,
    5. Yu X,
    6. Qadoumi M,
    7. Schmuth M,
    8. Sepp N,
    9. Nashan D,
    10. Rass K,
    11. Tüting T,
    12. Assaf C,
    13. Dippel E,
    14. Stadler R,
    15. Klemke CD and
    16. Goerdt S
    : Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia 22(2): 393-399, 2008. PMID: 18033314. DOI: 10.1038/sj.leu.2405044
    OpenUrlCrossRefPubMed
  29. ↵
    1. Teicher BA
    : Searching for molecular targets in sarcoma. Biochem Pharmacol 84(1): 1-10, 2012. PMID: 22387046. DOI: 10.1016/j.bcp.2012.02.009
    OpenUrlCrossRefPubMed
  30. ↵
    1. Marino N,
    2. Collins JW,
    3. Shen C,
    4. Caplen NJ,
    5. Merchant AS,
    6. Gökmen-Polar Y,
    7. Goswami CP,
    8. Hoshino T,
    9. Qian Y,
    10. Sledge GW Jr.. and
    11. Steeg PS
    : Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines. Clin Exp Metastasis 31(7): 771-786, 2014. PMID: 25086928. DOI: 10.1007/s10585-014-9667-0
    OpenUrlCrossRefPubMed
  31. ↵
    1. Yang JK,
    2. Yang JP,
    3. Tong J,
    4. Jing SY,
    5. Fan B,
    6. Wang F,
    7. Sun GZ and
    8. Jiao BH
    : Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma. J Neurooncol 131(2): 255-265, 2017. PMID: 27837435. DOI: 10.1007/s11060-016-2308-5
    OpenUrlCrossRef
  32. ↵
    1. Yang JK,
    2. Song J,
    3. Huo HR,
    4. Zhao YL,
    5. Zhang GY,
    6. Zhao ZM,
    7. Sun GZ and
    8. Jiao BH
    : DNM3, p65 and p53 from exosomes represent potential clinical diagnosis markers for glioblastoma multiforme. Ther Adv Med Oncol 9(12): 741-754, 2017. PMID: 29449895. DOI: 10.1177/1758834017737471
    OpenUrlCrossRef
  33. ↵
    1. Inokawa Y,
    2. Nomoto S,
    3. Hishida M,
    4. Hayashi M,
    5. Kanda M,
    6. Nishikawa Y,
    7. Takeda S,
    8. Fujiwara M,
    9. Koike M,
    10. Sugimoto H,
    11. Fujii T,
    12. Nakayama G,
    13. Yamada S,
    14. Tanaka C,
    15. Kobayashi D and
    16. Kodera Y
    : Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. Onco Targets Ther 6: 1417-1424, 2013. PMID: 24143113. DOI: 10.2147/OTT.S51913
    OpenUrlCrossRef
  34. ↵
    1. Shen J,
    2. Wang S,
    3. Zhang YJ,
    4. Kappil M,
    5. Wu HC,
    6. Kibriya MG,
    7. Wang Q,
    8. Jasmine F,
    9. Ahsan H,
    10. Lee PH,
    11. Yu MW,
    12. Chen CJ and
    13. Santella RM
    : Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 55(6): 1799-1808, 2012. PMID: 22234943. DOI: 10.1002/hep.25569
    OpenUrlCrossRefPubMed
  35. ↵
    1. Gu C,
    2. Yao J and
    3. Sun P
    : Dynamin 3 suppresses growth and induces apoptosis of hepatocellular carcinoma cells by activating inducible nitric oxide synthase production. Oncol Lett 13(6): 4776-4784, 2017. PMID: 28599479. DOI: 10.3892/ol.2017.6057
    OpenUrlCrossRefPubMed
  36. ↵
    1. Ma Y,
    2. Guan L,
    3. Han Y,
    4. Zhou Y,
    5. Li X,
    6. Liu Y,
    7. Zhang X,
    8. Zhang W,
    9. Li X,
    10. Wang S and
    11. Lu W
    : siPRDX2-elevated DNM3 inhibits the proliferation and metastasis of colon cancer cells via AKT signaling pathway. Cancer Manag Res 11: 5799-5811, 2019. PMID: 31388312. DOI: 10.2147/CMAR.S193805
    OpenUrlCrossRef
  37. ↵
    1. Lin S,
    2. Tan L,
    3. Luo D,
    4. Peng X,
    5. Zhu Y and
    6. Li H
    : Linc01278 inhibits the development of papillary thyroid carcinoma by regulating miR-376c-3p/DNM3 axis. Cancer Manag Res 11: 8557-8569, 2019. PMID: 31572010. DOI: 10.2147/CMAR.S217886
    OpenUrlCrossRef
  38. ↵
    1. Zhang HJ,
    2. Yuan GL,
    3. Liang QL,
    4. Peng X,
    5. Cheng SA,
    6. Jiang L,
    7. Liu Q,
    8. Zhang XC,
    9. Huang Z and
    10. Zeng Y
    : Progress of dynamin 3 in tumors. Int J Clin Exp Med 10(11): 15060-15063, 2017.
    OpenUrl
  39. ↵
    1. Jiang L,
    2. Liang QL,
    3. Liang WM,
    4. Zhang HJ,
    5. Huang J,
    6. Yuan GL,
    7. Peng XX,
    8. Cheng SA,
    9. Huang ZG and
    10. Zhang XN
    : Construction of a recombinant eukaryotic expression vector containing DNM3 gene and its expression in colon cancer cells. Onco Targets Ther 11: 6665-6671, 2017. PMID: 30349300. DOI: 10.2147/OTT.S176388
    OpenUrlCrossRef
  40. ↵
    1. Meindl A,
    2. Hellebrand H,
    3. Wiek C,
    4. Erven V,
    5. Wappenschmidt B,
    6. Niederacher D,
    7. Freund M,
    8. Lichtner P,
    9. Hartmann L,
    10. Schaal H,
    11. Ramser J,
    12. Honisch E,
    13. Kubisch C,
    14. Wichmann HE,
    15. Kast K,
    16. Deissler H,
    17. Engel C,
    18. Müller-Myhsok B,
    19. Neveling K,
    20. Kiechle M,
    21. Mathew CG,
    22. Schindler D,
    23. Schmutzler RK and,
    24. Hanenberg H
    : Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42(5): 410-414, 2010. PMID: 20400964. DOI: 10.1038/ng.569
    OpenUrlCrossRefPubMed
  41. ↵
    1. Wu M,
    2. Sheng Z,
    3. Jiang L,
    4. Liu Z,
    5. Bi Y and
    6. Shen Y
    : Overexpression of RAD51B predicts a preferable prognosis for non-small cell lung cancer patients. Oncotarget 8: 91471-91480, 2017. PMID: 29207658. DOI: 10.18632/oncotarget.20676
    OpenUrlCrossRef
  42. ↵
    1. Heim S,
    2. Nilbert M,
    3. Vanni R,
    4. Floderus UM,
    5. Mandahl N,
    6. Liedgren S,
    7. Lecca U and
    8. Mitelman F
    : A specific translocation, t(12;14)(q14-15;q23-24), characterizes a subgroup of uterine leiomyomas. Cancer Genet Cytogenet 32: 13-17, 1988. PMID: 3355995. DOI: 10.1016/0165-4608(88)90305-6
    OpenUrlCrossRefPubMed
  43. ↵
    1. Schoenmakers EF,
    2. Huysmans C and
    3. Van de Ven WJ
    : Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. Cancer Res 59(1): 19-23, 1999. PMID: 9892177.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Nagathihalli NS and
    2. Nagaraju G
    : RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Biochim Biophys Acta 1816(2): 209-218, 2011. PMID: 21807066. DOI: 10.1016/j.bbcan.2011.07.004
    OpenUrlCrossRefPubMed
    1. Thacker J
    : The RAD51 gene family, genetic instability and cancer. Cancer Lett 219(2): 125-135, 2005. PMID: 15723711. DOI: 10.1016/j.canlet.2004.08.018
    OpenUrlCrossRefPubMed
    1. Zhang X,
    2. Ma N,
    3. Yao W,
    4. Li S and
    5. Ren Z
    : RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer. Cancer Cell Int 19: 356, 2019. PMID: 31889908. DOI: 10.1186/s12935-019-1077-6
    OpenUrlCrossRef
  47. ↵
    1. Maacke H,
    2. Jost K,
    3. Opitz S,
    4. Miska S,
    5. Yuan Y,
    6. Hasselbach L,
    7. Lüttges J,
    8. Kalthoff H and
    9. Stürzbecher HW
    : DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 19(23): 2791-2795, 2000. PMID: 10851081. DOI: 10.1038/sj.onc.1203578
    OpenUrlCrossRefPubMed
  48. ↵
    1. Nowacka-Zawisza M,
    2. Wiśnik E,
    3. Wasilewski A,
    4. Skowrońska M,
    5. Forma E,
    6. Bryś M,
    7. Różański W and
    8. Krajewska WM
    : Polymorphisms of homologous recombination RAD51, RAD51B, XRCC2, and XRCC3 genes and the risk of prostate cancer. Anal Cell Pathol (Amst) 2015: 828646, 2015. PMID: 26339569. DOI: 10.1155/2015/828646
    OpenUrlCrossRef
  49. ↵
    1. Nowacka-Zawisza M,
    2. Raszkiewicz A,
    3. Kwasiborski T,
    4. Forma E,
    5. Bryś M,
    6. Różański W and
    7. Krajewska WM
    : RAD51 and XRCC3 polymorphisms are associated with increased risk of prostate cancer. J Oncol 2019: 2976373, 2019. PMID: 31186630. DOI: 10.1155/2019/2976373
    OpenUrlCrossRef
  50. ↵
    1. Krumm A,
    2. Barckhausen C,
    3. Kücük P,
    4. Tomaszowski KH,
    5. Loquai C,
    6. Fahrer J,
    7. Krämer OH,
    8. Kaina B and
    9. Roos WP
    : Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2-triggered drug resistance. Cancer Res 76(10): 3067-3077, 2016. PMID: 26980768. DOI: 10.1158/0008-5472.CAN-15-2680
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Tennstedt P,
    2. Fresow R,
    3. Simon R,
    4. Marx A,
    5. Terracciano L,
    6. Petersen C,
    7. Sauter G,
    8. Dikomey E and
    9. Borgmann K
    : RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. Int J Cancer 132(9): 2118-2126, 2013. PMID: 23065657. DOI: 10.1002/ijc.27907
    OpenUrlCrossRefPubMed
  52. ↵
    1. Michalska MM,
    2. Samulak D,
    3. Romanowicz H and
    4. Smolarz B
    : Association of polymorphisms in the 5’ untranslated region of RAD51 gene with risk of endometrial cancer in the Polish population. Arch Gynecol Obstet 290(5): 985-991, 2014. PMID: 24930116. DOI: 10.1007/s00404-014-3305-6
    OpenUrlCrossRef
  53. ↵
    1. Hannay JA,
    2. Liu J,
    3. Zhu QS,
    4. Bolshakov SV,
    5. Li L,
    6. Pisters PW,
    7. Lazar AJ,
    8. Yu D,
    9. Pollock RE and
    10. Lev D
    : Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 6(5): 1650-1660, 2007. PMID: 17513613. DOI: 10.1158/1535-7163.MCT-06-0636
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Welsh JW,
    2. Ellsworth RK,
    3. Kumar R,
    4. Fjerstad K,
    5. Martinez J,
    6. Nagel RB,
    7. Eschbacher J and
    8. Stea B
    : Rad51 protein expression and survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 74(4): 1251-1255, 2009. PMID: 19545791. DOI: 10.1016/j.ijrobp.2009.03.018
    OpenUrlCrossRefPubMed
  55. ↵
    1. Sidaraite A,
    2. Liutkeviciene R,
    3. Glebauskiene B,
    4. Vilkeviciute A and
    5. Kriauciuniene L
    : Associations of cholesteryl ester transfer protein (CETP) gene variants with pituitary adenoma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 164(2): 189-195, 2020. PMID: 31012439. DOI: 10.5507/bp.2019.016
    OpenUrlCrossRef
  56. ↵
    1. Liutkeviciene R,
    2. Vilkeviciute A,
    3. Morkunaite G,
    4. Glebauskiene B and
    5. Kriauciuniene L
    : SIRT1 (rs3740051) role in pituitary adenoma development. BMC Med Genet 20(1): 185, 2019. PMID: 31747893. DOI: 10.1186/s12881-019-0892-x
    OpenUrlCrossRef
  57. ↵
    1. Donaldson P,
    2. Daly A,
    3. Ermini L and
    4. Bevitt D
    : Genetics of Complex Disease, 1st edition. Garland Science, Taylor Francis Group, pp. 151, 2015.
  58. ↵
    1. Rowley M,
    2. Grothey E and
    3. Couch FJ
    : The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia 9: 109-118, 2004. PMID: 15300007. DOI: 10.1023/B:JOMG.0000037156.64331.3f
    OpenUrlCrossRefPubMed
  59. ↵
    1. Fan W,
    2. Huang X,
    3. Chen C,
    4. Gray J and
    5. Huang T
    : TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Cancer Res 64: 5132-5139, 2004. PMID: 15289316. DOI: 10.1158/0008-5472.CAN-04-0615
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Zhang Z,
    2. Chen C,
    3. Guo W,
    4. Zheng S,
    5. Sun Z and
    6. Geng X
    : DNM3 attenuates hepatocellular carcinoma growth by activating p53. Med Sci Monit 22(1): 197-205, 2016. PMID: 26784388. DOI: 10.12659/msm.896545
    OpenUrlCrossRef
  61. ↵
    1. Lee YY,
    2. Do IG,
    3. Park YA,
    4. Choi JJ,
    5. Song SY,
    6. Kim CJ,
    7. Kim MK,
    8. Song TJ,
    9. Park HS,
    10. Choi CH,
    11. Kim TJ,
    12. Kim BG,
    13. Lee JW and
    14. Bae DS
    : Low dynamin 2 expression is associated with tumor invasion and metastasis in invasive squamous cell carcinoma of cervix. Cancer Biol Ther 10(4): 329-335, 2010. PMID: 20574164. DOI: 10.4161/cbt.10.4.12275
    OpenUrlCrossRefPubMed
  62. ↵
    1. Johnson J,
    2. Healey S,
    3. Khanna KK and
    4. Chenevix-Trench G
    : Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families. Breast Cancer Res Treat 129: 255-263, 2011. PMID: 21533530. DOI: 10.1007/s10549-011-1539-6
    OpenUrlCrossRefPubMed
  63. ↵
    1. Thomas G,
    2. Jacobs KB,
    3. Kraft P,
    4. Yeager M,
    5. Wacholder S,
    6. Cox DG,
    7. Hankinson SE,
    8. Hutchinson A,
    9. Wang Z,
    10. Yu K,
    11. Chatterjee N,
    12. Garcia-Closas M,
    13. Gonzalez-Bosquet J,
    14. Prokunina-Olsson L,
    15. Orr N,
    16. Willett WC,
    17. Colditz GA,
    18. Ziegler RG,
    19. Berg CD,
    20. Buys SS,
    21. McCarty CA,
    22. Feigelson HS,
    23. Calle EE,
    24. Thun MJ,
    25. Diver R,
    26. Prentice R,
    27. Jackson R,
    28. Kooperberg C,
    29. Chlebowski R,
    30. Lissowska J,
    31. Peplonska B,
    32. Brinton LA,
    33. Sigurdson A,
    34. Doody M,
    35. Bhatti P,
    36. Alexander BH,
    37. Buring J,
    38. Lee IM,
    39. Vatten LJ,
    40. Hveem K,
    41. Kumle M,
    42. Hayes RB,
    43. Tucker M,
    44. Gerhard DS,
    45. Fraumeni JF Jr.,
    46. Hoover RN,
    47. Chanock SJ and
    48. Hunter DJ
    : A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41(5): 579-584, 2009. PMID: 19330030. DOI: 10.1038/ng.353
    OpenUrlCrossRefPubMed
  64. ↵
    1. Trainer AH,
    2. James PA,
    3. Bojesen SE,
    4. Bokmand S,
    5. Nevanlinna H,
    6. Mattson J,
    7. Friedman E,
    8. Laitman Y,
    9. Palli D,
    10. Masala G,
    11. Zanna I,
    12. Ottini L,
    13. Giannini G,
    14. Hollestelle A,
    15. Ouweland AM,
    16. Novaković S,
    17. Krajc M,
    18. Gago-Dominguez M,
    19. Castelao JE,
    20. Olsson H,
    21. Hedenfalk I,
    22. Easton DF,
    23. Pharoah PD,
    24. Dunning AM,
    25. Bishop DT,
    26. Neuhausen SL,
    27. Steele L,
    28. Houlston RS,
    29. Garcia-Closas M,
    30. Ashworth A and
    31. Swerdlow AJ
    1. Orr N,
    2. Lemnrau A,
    3. Cooke R,
    4. Fletcher O,
    5. Tomczyk K,
    6. Jones M,
    7. Johnson N,
    8. Lord CJ,
    9. Mitsopoulos C,
    10. Zvelebil M,
    11. McDade SS,
    12. Buck G,
    13. Blancher C; KConFab Consortium
    , Trainer AH, James PA, Bojesen SE, Bokmand S, Nevanlinna H, Mattson J, Friedman E, Laitman Y, Palli D, Masala G, Zanna I, Ottini L, Giannini G, Hollestelle A, Ouweland AM, Novaković S, Krajc M, Gago-Dominguez M, Castelao JE, Olsson H, Hedenfalk I, Easton DF, Pharoah PD, Dunning AM, Bishop DT, Neuhausen SL, Steele L, Houlston RS, Garcia-Closas M, Ashworth A and Swerdlow AJ: Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nat Genet 44(11): 1182-1184, 2012. PMID: 23001122. DOI: 10.1038/ng.2417
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
TBX15 rs98422, DNM3 rs1011731, RAD51B rs8017304, and rs2588809 Gene Polymorphisms and Associations With Pituitary Adenoma
GABIJA JUKNYTĖ, INGA LAURINAITYTĖ, ALVITA VILKEVIČIŪTĖ, GRETA GEDVILAITĖ, BRIGITA GLEBAUSKIENĖ, LORESA KRIAUČIŪNIENĖ, RASA LIUTKEVIČIENĖ
In Vivo Mar 2021, 35 (2) 815-826; DOI: 10.21873/invivo.12322
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords